Prevalence of Antibodies to Hepatitis C Virus in Italian Patients With Hepatocellular Carcinoma

Colombo, Massimo; Choo, Qui‐Lim; Ninno, E. Del; Dioguardi, N; Kuo, George; Donato, Maria Francesca; Tommasini, M.; Houghton, Michael

doi:10.1016/s0140-6736(89)91016-7

Cited by 623 publications

(248 citation statements)

References 13 publications

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…12 In European and North American countries, it most often develops in patients with chronic liver disease, as a natural evolution or a complication of the illness. 13 Thus, liver cirrhosis represents the strongest risk factor for the development of HCC. 13,14 Surveillance programs have been recommended by both the EASL and AISF for patients with liver cirrhosis to ensure detection of early HCC at a more suitable stage for treatment and with a better clinical outcome.…”

Section: Discussionmentioning

confidence: 99%

“…13 Thus, liver cirrhosis represents the strongest risk factor for the development of HCC. 13,14 Surveillance programs have been recommended by both the EASL and AISF for patients with liver cirrhosis to ensure detection of early HCC at a more suitable stage for treatment and with a better clinical outcome. 15 So far, a-FP measurement is the only marker used in clinical practice for serologic diagnosis of HCC, although it has questionable reliability.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

SCCA antigen combined with alpha‐fetoprotein as serologic markers of HCC

Giannelli

Marinosci

Trerotoli

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Because of its increased incidence in the last decade and the estimated further increase in the next 2 decades, HCC is arousing great interest. In Europe and North America, it commonly develops on cirrhotic livers, and surveillance programs have therefore been suggested to identify early HCC, at a stage when it remains suitable for surgical therapy and has a better clinical outcome. The only serologic marker used in clinical practice is a-fetoprotein (a-FP), but its sensitivity is poor. In our study, 120 patients with HCC and 90 patients with liver cirrhosis were investigated. We report for the first time to our knowledge that as a marker of HCC, the squamous cell carcinoma (SCCA) antigen has high sensitivity (84.2%) but low specificity (48.9%). However, the combination of a-FP and SCCA yielded a correct serologic diagnosis in 90.83% of the HCC patients. A small percentage of patients remain undetected, likely because of the low specificity of SCCA. In conclusion, the combined use of a-FP and SCCA antigen represents a more powerful tool for the serologic detection of HCC. ' 2005 Wiley-Liss, Inc.Key words: SCCA; HCC; a-fetoprotein; diagnosis; cirrhosis Hepatocellular carcinoma (HCC) is becoming a major health problem worldwide as it represents the fifth most common cancer in the world and the third most common cause of cancer-related death. In Europe and the USA, the incidence rates of HCC have strongly increased in the last decade and will likely increase further in the upcoming 2 decades due to hepatitis C virus infection, 1,2 although there is some controversy as to whether it is directly responsible for liver cancer development. [3][4][5] In Western and North American countries, HCC commonly develops in cirrhotic livers whatever the etiology, so that liver cirrhosis by itself represents the strongest risk factor. 3,5,6 The clinical outcome and the prognosis of HCC are unsatisfactory, even if in developed countries a major improvement of treatment and survival has been achieved in patients with HCC at the initial stage. 7 Therefore, surveillance programs aimed at detecting early stage HCC have been recommended by the European Association for the Study of the Liver (EASL) as well as the Italian Association for the Study of the Liver (AISF). These programs are based on the use of ultrasound tomography and a-fetoprotein (a-FP). The reliability of imaging techniques has greatly improved in the last years but such diagnostic procedures are expensive and subject to interpretation. On the other hand, as the only diagnostic serologic test currently available in clinical practice, a-FP has too low a sensitivity and specificity; based on receiving operating characteristic (ROC) curve analysis, its sensitivity reaches only 60%. 8 It has been reported that the squamous cell carcinoma antigen (SCCA) is overexpressed in HCC tissues. 9 SCCA is a component of the high molecular weight serine protease inhibitors named serpins. 10 A different expressi...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

SCCA antigen combined with alpha‐fetoprotein as serologic markers of HCC

Giannelli

Marinosci

Trerotoli

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…International trends in primary liver cancer incidence rates during 1973 to 2007 revealed that most ESR for primary liver cancer was a range from 19 to 26.7 per 100,000 men and from 4.8 to 8.7 per 100,000 women in some Asian populations (Zhang et al, 2015). HCG differences in the incidence rates in different geographical areas are correlated with hepatitis B and C rates because chronic viral hepatitis has been reported as an important risk factor for HCC in endemic areas (Chisari et al, 1989;Colombo et al, 1989;Idilman et al, 1998). This is despite the fact that approximately 45 million and 15 million people worldwide suffer from chronic hepatitis B and C (Kar, 2014).…”

Section: Incidence and Mortality Of Liver Cancer In The Wordmentioning

confidence: 99%

Incidence and mortality of liver cancer and their relationship with the human development index in the world

Arabsalmani¹,

Mirzaei²,

Ghoncheh³

et al. 2016

Biomed Res Ther

View full text Add to dashboard Cite

Abstract-Background: Information on the incidence and mortality of liver cancer can be useful for health programs and research activities, and with regard to the possible role of the HDI and liver cancer, this study aimed to investigate incidence and mortality from the cancer and their relationship with the indicator and its components in 2012 in world. Methods: In this ecologic study, data were extracted from GLOBOCAN in 2012. Data on HDI and its components were extracted from the World Bank. The number and standardized incidence and mortality rates of liver cancer were reported by regions in the world. Data were analyzed by SPSS software and Correlation coefficient test. Results: There was a total of 782,451 incidence cases. Of these patients, 228, 082 cases (29.15 %) were women and 554, 369 cases (70.85 %) men, and there were 745,533 deaths. Of the deaths, 224, 492 cases (30.11 %) occurred in women and 521, 041 cases (69.89 %) men were recorded in the world in 2012. Results showed that there was a significant inverse correlation between age-specific incidence rate (ASIR) and HDI (r=-0.345, p≤0.001), as well significant inverse correlation was seen between age-specific mortality rate (ASMR), and HDI and its components. Conclusion: Liver cancer incidence and mortality are higher in the medium HDI countries. The relationship between the standardized incidence and mortality of liver cancer with HDI and its components, including life expectancy at birth, mean years of schooling and income level per person was significantly negative.

show abstract

“…Two large studies, one from Italy and another from Spain, noted that the majority of patients with HCC tested positive for anti-HCV. 3,4 However, these were cross-sectional surveys done in patients who already had established HCC, indicating an association but not cause and effect. It was against this background that Kiyosawa et al showed that a substantial proportion of Japanese patients with HBV-negative HCC tested positive for anti-HCV.…”

Section: Adrian M Di Biscegliementioning

confidence: 99%